Skip to content 
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. The company was incorporated in 2018 and is based in Fremont, California. more
| Dec '24 | Dec '25 | |||||
|---|---|---|---|---|---|---|
| Total Revenue | 25.14M | 74.21M | [{"date":"2024-12-31","value":33.88,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Cost of Revenue | 16.54M | 32.51M | [{"date":"2024-12-31","value":50.87,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Gross Profit | 8.61M | 41.70M | [{"date":"2024-12-31","value":20.64,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Gross Margin | 34.23% | 56.20% | [{"date":"2024-12-31","value":60.92,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Operating Expenses | 74.71M | 105.55M | [{"date":"2024-12-31","value":70.78,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Operating Income | (49.57M) | (31.33M) | [{"date":"2024-12-31","value":-4956800000,"profit":false},{"date":"2025-12-31","value":-3133400000,"profit":false}] | |||
| Total Non-Operating Income/Expense | 2.51M | 2.18M | [{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":86.92,"profit":true}] | |||
| Pre-Tax Income | (47.06M) | (29.15M) | [{"date":"2024-12-31","value":-4706000000,"profit":false},{"date":"2025-12-31","value":-2915400000,"profit":false}] | |||
| Income Taxes | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Income After Taxes | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Income From Continuous Operations | (47.07M) | (29.82M) | [{"date":"2024-12-31","value":-4707300000,"profit":false},{"date":"2025-12-31","value":-2981900000,"profit":false}] | |||
| Income From Discontinued Operations | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Net Income | (47.07M) | (29.82M) | [{"date":"2024-12-31","value":-4707300000,"profit":false},{"date":"2025-12-31","value":-2981900000,"profit":false}] | |||
| EPS (Diluted) | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| ALMR | |
|---|---|
| ROA (LTM) | -13.53% |
| ROE (LTM) | -33.58% |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| ALMR | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 21.75 |
| P/B | 0.00 |
| EV/R | 21.99 |
| EV/Ebitda | NM |
Alamar Biosciences, Inc. Common Stock (ALMR) share price today is $23.96
Yes, Indians can buy shares of Alamar Biosciences, Inc. Common Stock (ALMR) on Vested. To buy
Yes, you can purchase fractional shares of Alamar Biosciences, Inc. Common Stock (ALMR) via the Vested app. You can start investing in Alamar Biosciences, Inc. Common Stock (ALMR) with a minimum investment of $1.
You can invest in shares of Alamar Biosciences, Inc. Common Stock (ALMR) via Vested in three simple steps:
The 52-week high price of Alamar Biosciences, Inc. Common Stock (ALMR) is $27.2. The 52-week low price of Alamar Biosciences, Inc. Common Stock (ALMR) is $17.
The price-to-earnings (P/E) ratio of Alamar Biosciences, Inc. Common Stock (ALMR) is
The price-to-book (P/B) ratio of Alamar Biosciences, Inc. Common Stock (ALMR) is 0.00
The dividend yield of Alamar Biosciences, Inc. Common Stock (ALMR) is 0.00%
The market capitalization of Alamar Biosciences, Inc. Common Stock (ALMR) is $1.61B
The stock symbol (or ticker) of Alamar Biosciences, Inc. Common Stock is ALMR
Consider the share price of Alamar Biosciences, Inc. Common Stock as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Alamar Biosciences, Inc. Common Stock has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Alamar Biosciences, Inc. Common Stock shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Alamar Biosciences, Inc. Common Stock stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Alamar Biosciences, Inc. Common Stock and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Alamar Biosciences, Inc. Common Stock stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
